Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2855 Gazelle Court CARLSBAD CA 92010 |
Tel: | N/A |
Website: | https://www.ionispharma.com |
IR: | See website |
Key People | ||
Brett P. Monia Chief Executive Officer, Director | Elizabeth L. Hougen Chief Financial Officer, Executive Vice President - Finance | C. Frank Bennett Executive Vice President, Chief Scientific Officer |
Joseph T. Baroldi Executive Vice President, Chief Business Officer | Richard S. Geary Executive Vice President, Chief Development Officer | Kyle Jenne Executive Vice President - commercial |
Eugene Schneider Executive Vice President, Chief Clinical Development Officer | Eric E. Swayze Executive Vice President - Research | Patrick R. O'Neil Chief Legal Officer, General Counsel and Corporate Secretary |
Business Overview |
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company's products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN). |
Financial Overview |
For the fiscal year ended 31 December 2023, Ionis Pharmaceuticals Inc revenues increased 34% to $787.6M. Net loss increased 36% to $366.3M. Revenues reflect Collaborative agreement revenue increase of 70% to $352.7M, WAINUA joint development revenue increase of 65% to $126.4M, Other commercial revenue increase from $31M to $68.2M. Higher net loss reflects Gain (loss) on sale of real estate asset decrease from $149.6M (income) to $161K (expense). |
Employees: | 927 as of Feb 15, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $5,130M as of Dec 31, 2023 |
Annual revenue (TTM): | $787.65M as of Dec 31, 2023 |
EBITDA (TTM): | -$340.88M as of Dec 31, 2023 |
Net annual income (TTM): | -$366.29M as of Dec 31, 2023 |
Free cash flow (TTM): | -$331.32M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 145,751,797 as of Feb 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |